On Wednesday, at the 75th Annual Meeting of the College on Problems of Drug Dependence, Nektar Therapeutics (NKTR) announced positive results for the human abuse liability study for NKTR-181 which is a very promising new drug candidate in Nektar's pipeline that is being developed as an analgesic for the treatment of chronic pain. According to Nektar's President and CEO Howard Robin, "The NKTR-181 molecule has been designed to enter the CNS slowly to reduce the dopamine rush and its associated euphoria that lead to the abuse of and addiction to current opioid analgesics." Read about the results here. In other words NKTR-181 is designed to be the first non-addictive opioid painkiller.
The problem of addiction and abuse...
Only subscribers can access this article, which is part of the PRO research library covering 3,618 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: